EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus

June 24, 2022

8 June 2022
EMA/175959/2021 Rev.2
Human Medicines Division

Regulatory and procedural requirements

Introduction

In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may be necessary to modify the authorised human coronavirus vaccines composition so as to protect against new or multiple variant strain(s). Such changes, which include the replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences, should be considered as variations to the marketing authorisation in accordance to the Commission Regulation (EC) No 1234/2008 as amended by Commission Delegated Regulation (EU) 2021/756, provided the technological platform of the vaccine remains similar. The same approach should be followed for all human coronaviruses as set out in the Commission Delegated Regulation (EU) 2021/756. This guideline lays down the procedural aspects related to the submission of a variation to change the composition of a marketing authorisation for COVID-19 vaccines in the centralised procedure.

Download Procedural Guidance

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




EMA MAH Several vials of COVID-19 vaccines lined up on a table.

June 2, 2022

EMA: Procedural advice for vaccine platform technology master 5 file (vPTMF) certification (DRAFT)

This document is intended to provide advice to marketing authorisation (MA) applicants and marketing authorisation holders (MAHs) on issues associated with the submission, evaluation, certification...

Read the Full Article
EMA Europe Petri dish with bacteria growing.

June 21, 2022

Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans - in relation to implementing measures under Article 37(5) of Regulation

Regulatory and Procedural Guideline May 2022 EMA/CVMP/678496/2021-rev Introduction “According to Article 37(5) of Regulation (EU) 2019/6 (‘the Regulation’), the European Commission shall adopt...

Read the Full Article
FDA EMA

June 22, 2022

Maximising on Scientific Advice Procedures in Europe

A unique opportunity to interact with medicine regulators in Europe Are you considering requesting scientific advice in Europe? We can help you navigate the various procedures within the European...

Read the Full Article